Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants
Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants experiencing known or suspected coronary artery disease, and showed that Optison Myocardial Contrast Echocardiography (MCE) tests were comparable to the standard clinical tests, either SPECT or coronary angiography, according to San Diego-based MBI. MBI now plans to proceed to phase III clinical trials for the agent.
Meanwhile, sales of Optison continue outside the U.S. Optison was cleared for sale in Europe in 1998 (SCAN 5/27/98), and is sold there by MBIs marketing partner, St. Louis-based Mallinckrodt. Earlier this year, MBI signed a licensing agreement with Chugai Pharmaceuticals for marketing of the agent in Japan, South Korea, and Taiwan (SCAN 6/9/99).
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.